The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit
3.6.2023 08:11:00 EEST | Business Wire | Press release
President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/
Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)
As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals.
“We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every big, complicated society is that there’s an incredibly built-in resistance to being the second, third, fourth, or 100th person to do the same thing, even though it’s been proven to work. Which is exactly the reverse of what we should be doing.”
Reflecting on his time in office during the 1990s, President Clinton said that we could learn much from the example of former South African President Nelson Mandela when it comes to uniting people behind a common cause for good.
“Everyone wants to believe they have some piece to add to life’s great puzzle,” he said. “You need converts to do anything big, and we’ve got to get more zealous converts. Nelson Mandela was a genius at this. He was the best I ever saw. He never tried to make people feel bad for what they hadn’t done. He tried to make people feel good about what they could do.”
Having long been a campaigner on the dangers of the opioid epidemic and a supporter of the PSMF since its inception, President Clinton suggested that it is important to focus on collaborating for future good rather than blaming and shaming when it comes to medical errors.
“No one wants to see innocent people die, and very few are hard-hearted enough not to care,” he said. “You don’t have to save everybody; you just have to save everybody that you can.”
Dr. Michael Ramsay, chief executive officer of the PSMF, told the audience that there is much cause for optimism when it comes to meeting the target of zero preventable deaths by 2030. “I think there’s a future now to patient safety,” he said. “I think things are going to start happening remarkably fast. Technology is changing, we’re gathering more data, and we’ve got more and more people involved in this movement.”
Jeremy Hunt, chancellor of the exchequer of the United Kingdom, delivered a video message to the Summit in which he applauded the difference made by the PSMF over the last decade. “We now have the World Health Organization doing an annual World Patient Safety Day, a 10-year plan to reduce preventable deaths, and we had a ministerial summit this year in Montreux in Switzerland with more than 100 countries represented. We’re making great progress, but there’s a lot of work to do. Even one preventable death is too many. We should be aiming for zero.”
Following on from President Clinton’s remarks about creating the right culture for change within healthcare, Anthony Staines, patient safety program director, Fédération des hôpitaux vaudois, Switzerland, described the need to address the failings of implementation science, a topic also addressed in a talk from Francisco Valero-Cuevas, a professor at the University of Southern California.
“There are many prevention and mitigation solutions, but they are only partly and unsystematically applied,” said Staines. “Science has brought us an expanding body of knowledge. The trouble is that it does not reach the patients.”
There were additional talks from Peter Ziese, chief medical officer at Philips, and Michelle Schreiber of the Centers for Medicare & Medicaid Services. Schreiber told the audience that while healthcare throughout the United States has made significant improvements in patient safety, the pandemic illustrated how our systems are still not durable and resilient enough for times of stress, and gaps in care and infrastructure continue to persist.
Mike Durkin and Sanaz Massoumi, chairman and chief operating officer of the PSMF respectively, gave addresses, and panel discussion topics included the media’s role in covering patient safety, opioid safety, and steps that can be taken in the journey to zero harm. Marcelo Ebrard Casaubón, secretary of foreign affairs of Mexico, received the Joe Kiani Humanitarian Award for his work in patient safety.
Finally, Kiani, founder of the PSMF, reflected on a decade of achievement and the path forward. “We started as a grassroots organization, and the grassroots movement has done so much,” he said. “I think our next step is to demand our elected officials to hardwire patient safety into our system and align the incentives so that every hospital puts evidence-based practices in place.”
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005417/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
